INmune Bio, Inc.INMBNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 63% recommend buying.

Consensus Rating

Buy

8 analysts·Limited coverage

63%

Rating Distribution

Strong Buy

00%

Buy

563%

Hold

225%

Sell

113%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 1449% higher.

Bear Case

$22.00

+1449%

Consensus

$22.00

+1449%

Bull Case

$22.00

+1449%

Price Range8 analysts

Low

Consensus

High

$22.00

Current Target

Current Price

$1.42

Upside to Target

$20.58

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-0.99(2 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+4920.01%

EPS—

FY2028

Rev+376.91%

EPS—

FY2029

Rev+202.48%

EPS—

Earnings Surprises

Beat rate:50%(6/12 quarters)

Avg surprise:-137.2%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Aug 22, 2024Scotiabank

Scotiabank starts INmune with Outperform on Alzheimer's potential

Target:$22.00

+221.2%from $6.85

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance